209 related articles for article (PubMed ID: 27275095)
1. (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.
Hu PH; Pan LH; Wong PT; Chen WH; Yang YQ; Wang H; Xiang JJ; Xu M
World J Gastroenterol; 2016 Jun; 22(21):5033-41. PubMed ID: 27275095
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
[TBL] [Abstract][Full Text] [Related]
3. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
[TBL] [Abstract][Full Text] [Related]
4. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines.
Ogasawara S; Yano H; Iemura A; Hisaka T; Kojiro M
Hepatology; 1996 Jul; 24(1):198-205. PubMed ID: 8707262
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
7. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
DU YF; Luo RC; Li GP; Li AM; Ding XM; Yan X; Huang K
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):460-2. PubMed ID: 18359714
[TBL] [Abstract][Full Text] [Related]
8. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
Zhou JM; Zhu XF; Liu ZC; Fu LW; Yang XP; Liang YJ; Pan QC
Ai Zheng; 2005 Aug; 24(8):935-9. PubMed ID: 16086869
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops.
Ma Y; Han CC; Li Y; Wang Y; Wei W
Biochem Biophys Res Commun; 2016 Sep; 478(2):964-9. PubMed ID: 27521890
[TBL] [Abstract][Full Text] [Related]
11. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.
Wang L; Park H; Chhim S; Ding Y; Jiang W; Queen C; Kim KJ
Mol Cancer Ther; 2012 Apr; 11(4):864-72. PubMed ID: 22351746
[TBL] [Abstract][Full Text] [Related]
12. VEGF, bFGF and their receptors at the fetal-maternal interface of the rhesus monkey.
Wei P; Yu FQ; Chen XL; Tao SX; Han CS; Liu YX
Placenta; 2004; 25(2-3):184-96. PubMed ID: 14972451
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.
Chen T; Yuan SJ; Wang J; Hu W
World J Gastroenterol; 2015 Sep; 21(35):10126-36. PubMed ID: 26401077
[TBL] [Abstract][Full Text] [Related]
14. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
[TBL] [Abstract][Full Text] [Related]
15. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma.
Ueki T; Koji T; Tamiya S; Nakane PK; Tsuneyoshi M
J Pathol; 1995 Dec; 177(4):353-61. PubMed ID: 8568589
[TBL] [Abstract][Full Text] [Related]
16. Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma.
Duan CL; Hou GH; Liu YP; Liang T; Song J; Han JK; Zhang C
Tumour Biol; 2014 Dec; 35(12):12205-15. PubMed ID: 25164610
[TBL] [Abstract][Full Text] [Related]
17. [Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1].
Chen FG; Wang JJ; Xue Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):665-8. PubMed ID: 19785953
[TBL] [Abstract][Full Text] [Related]
18. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
Zhang JB; Sun HC; Jia WD; Zhuang PY; Qian YB; Zhu XD; Kong LQ; Wang L; Wu WZ; Tang ZY
BMC Cancer; 2012 Oct; 12():439. PubMed ID: 23025904
[TBL] [Abstract][Full Text] [Related]
20. [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Zhai Y; Lu ZJ
Ai Zheng; 2003 Dec; 22(12):1301-6. PubMed ID: 14693056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
